Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $154,280.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 8,120 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.00, for a total value of $154,280.00. Following the completion of the sale, the insider directly owned 1,179,524 shares of the company’s stock, valued at $22,410,956. This represents a 0.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $15.77 on Friday. The stock’s 50 day simple moving average is $17.03 and its 200 day simple moving average is $15.20. Adaptive Biotechnologies Corporation has a twelve month low of $6.26 and a twelve month high of $20.76. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -39.42 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 48.73% and a negative net margin of 21.48%.The firm had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter in the prior year, the business earned ($0.23) earnings per share. The company’s revenue was up 51.0% on a year-over-year basis. On average, analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a report on Friday. JPMorgan Chase & Co. lifted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday. Morgan Stanley started coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price for the company. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.56.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares in the last quarter. Jennison Associates LLC lifted its position in Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after purchasing an additional 1,363,181 shares during the period. Summit Partners Public Asset Management LLC acquired a new stake in Adaptive Biotechnologies during the third quarter worth $14,934,000. Finally, First Trust Advisors LP boosted its stake in Adaptive Biotechnologies by 4,802.2% during the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock worth $8,636,000 after buying an additional 726,184 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.